Rolando Ania, MD
Payments from drug & device makers
Across 404 payments — averaging $27.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$3K
- AbbVie$2K
- UCB, Inc.$1K
- Neurocrine Biosciences, Inc.$877
- Pfizer$553
- SK Life Science, Inc.$535
- plus $4K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 1 | $2,636 |
| AbbVie(2 entities) | 80 | $1,509 |
| UCB, Inc. | 68 | $1,186 |
| Neurocrine Biosciences, Inc. | 35 | $877 |
| Pfizer | 36 | $553 |
| SK Life Science, Inc. | 37 | $535 |
| Lilly USA, LLC | 15 | $472 |
| Livanova USA, Inc. | 6 | $406 |
| Catalyst Pharmaceuticals, Inc. | 11 | $306 |
| Greenwich Biosciences, Inc. | 3 | $261 |
| Argenx US, Inc. | 10 | $260 |
| Lundbeck LLC | 11 | $219 |
| Amneal Pharmaceuticals LLC | 8 | $212 |
| Impel Pharmaceuticals Inc. | 14 | $208 |
| Neurelis, Inc. | 8 | $202 |
| Jazz Pharmaceuticals Inc. | 8 | $174 |
| AstraZeneca(2 entities) | 5 | $170 |
| Sumitomo Pharma America, Inc. | 9 | $164 |
| Tanabe Pharma America, Inc. | 7 | $163 |
| Otsuka America Pharmaceutical, Inc. | 5 | $107 |
| Eisai Inc. | 4 | $79 |
| Teva Pharmaceuticals USA, Inc. | 3 | $78 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $54 |
| Sunovion Pharmaceuticals Inc. | 4 | $49 |
| Biogen | 2 | $49 |
| Grifols USA, LLC | 2 | $42 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $41 |
| MDD US Operations, LLC | 1 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Averitas Pharma Inc. | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
How this compares
$11,165 in reported general payments places this provider in the 70th percentile of 145 neurology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Reno
- Melissa BlochReno$1.1M
- Lee GerwitzReno$415K
- Burton TabaacReno$287K
- G BigleyReno$134K
- Verena SamaraReno$64K
- Christopher WayReno$57K
- Frank QuaglieriReno$21K
- Timothy LouieReno$15K
- Yen-Yi PengReno$14K
- Danny TruongReno$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.